INVO Fertility's Days Sales Outstanding for the
three
months ended in Mar. 2026 was 10.53.
INVO Fertility's Days Inventory for the
three
months ended in Mar. 2026 was 15.95.
INVO Fertility's Days Payable for the
three
months ended in Mar. 2026 was 131.24.
Therefore, INVO Fertility's Cash Conversion Cycle (CCC) for the
three
months ended in Mar. 2026 was -104.76.
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
INVO Fertility Cash Conversion Cycle Related Terms
INVO Fertility Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for INVO Fertility's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IVF vs RMSL, ADMT, USAQ: Cash Conversion Cycle Comparison
For the Medical Devices subindustry, INVO Fertility's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
INVO Fertility Cash Conversion Cycle vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, INVO Fertility's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where INVO Fertility's Cash Conversion Cycle falls into.
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
INVO Fertility's Cash Conversion Cycle for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Cash Conversion Cycle of -104.76 mean?
INVO Fertility (IVF) has a Cash Conversion Cycle of -104.76 as of Mar. 2026. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on INVO Fertility and its competitors.
Is INVO Fertility's Cash Conversion Cycle too high?
INVO Fertility's current Cash Conversion Cycle is -104.76. Overall, INVO Fertility has a GF Score™ of 35/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does INVO Fertility's Cash Conversion Cycle compare to RMSL and ADMT?
INVO Fertility's Cash Conversion Cycle of -104.76 can be compared against companies in the Medical Devices & Instruments industry. The industry median Cash Conversion Cycle is 156.96. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Medical Devices & Instruments company?
The median Cash Conversion Cycle among Medical Devices & Instruments companies is 156.96, based on 815 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on INVO Fertility and its competitors. For the Medical Devices & Instruments industry, the median Cash Conversion Cycle is 156.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. INVO Fertility's current Cash Conversion Cycle is -104.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is INVO Fertility stock overvalued right now?
Based on GuruFocus' analysis, INVO Fertility (IVF) is currently considered Possible Value Trap. The stock's GF Value™ is $134.71, compared to a current price of $1.13 — trading 99.2% below its estimated fair value. The current Cash Conversion Cycle is -104.76. INVO Fertility's overall GF Score™ is 35/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For INVO Fertility (IVF), the current Cash Conversion Cycle is -104.76 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is INVO Fertility (IVF) Overvalued in 2026?
Based on GuruFocus' analysis, INVO Fertility stock appears to be undervalued.
The current stock price of $1.13 is trading 99.2% below its estimated GF Value™ of $134.71.
GuruFocus considers INVO Fertility to be Possible Value Trap.
Key valuation signals for IVF:
Cash Conversion Cycle: -104.76
GF Value™: $134.71 vs. price of $1.13 (99.2% below fair value)
No single metric tells the full story. See the IVF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
INVO Fertility Inc is a healthcare services fertility company dedicated to expanding assisted reproductive technology (ART) care to patients in need. It is offering the intravaginal culture (IVC) procedure enabled by INVOcell medical device (INVOcell). The INVOcell is a proprietary and revolutionary medical device, and the first to allow fertilization and early embryo development to take place in vivo within the woman's body. The company's segments include: The Clinics Services operating segment consisting of financial information for WFI and the Atlanta Clinic and The INVOcell Device operating segment consisting of financial information relating to the manufacture and sales of the INVOcell.
35GF Score
Get the complete analysis for IVF
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IVF has been successfully added to your 
